Literature DB >> 11733634

Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1.

T Yamauchi1, M Quillard, S Takahashi, M Nguyen-Khoa.   

Abstract

BACKGROUND: Dialysis patients with primary hyperoxaluria are exposed to risks and hazards associated with calcium oxalate salt deposition in body tissues, since regular dialysis treatment does not adequately correct hyperoxalaemia. The purpose of this study was to evaluate oxalate mass removal using various dialysis modes in a patient suffering from primary hyperoxaluria type 1 (PH1).
METHODS: Oxalate kinetics during daily haemodialysis was compared with that of standard haemodialysis (STD HD) and haemodiafiltration (HDF) using high flux dialysers (FB 170 H and FB 210 U, Transdial, Paris, France). All dialysis sessions lasted for 4 h. Blood was withdrawn and spent dialysate was collected in plastic bags every hour to evaluate mass removal. Oxalate concentration in plasma and in spent dialysate was determined by an enzymatic method. Oxalate generation, distribution volume and tissue deposition were calculated using single-pool models adapted from previous studies.
RESULTS: Although no significant difference was found in mass removal per session between dialysis strategies and dialyser types, weekly mass removal with daily HD was about 2 times greater than with STD HD or HDF. Even when daily HD was performed, the oxalate generation rate-mass removal ratio (G/R ratio) remained at a value of approximately 2.
CONCLUSION: Although daily HD sessions led to a substantial increase in weekly oxalate removal, all three types of renal replacement therapy were insufficient to compensate for estimated oxalate generation. To eliminate sufficient amounts of oxalate generated in PH1 patients, at least 8 h of daily dialysis with a high-flux membrane would probably be required. Renal replacement therapy for PH1 patients needs be improved further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733634     DOI: 10.1093/ndt/16.12.2407

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

2.  Oxalate nephropathy associated with chronic pancreatitis.

Authors:  Claire Cartery; Stanislas Faguer; Alexandre Karras; Olivier Cointault; Louis Buscail; Anne Modesto; David Ribes; Lionel Rostaing; Dominique Chauveau; Patrick Giraud
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-07       Impact factor: 8.237

Review 3.  Primary and secondary hyperoxaluria: Understanding the enigma.

Authors:  Bhavna Bhasin; Hatice Melda Ürekli; Mohamed G Atta
Journal:  World J Nephrol       Date:  2015-05-06

4.  Restrictive cardiomyopathy in a patient with primary hyperoxaluria type II.

Authors:  Matthias R Schulze; Rolf Wachter; Alexander Schmeisser; Rainer Fischer; Ruth H Strasser
Journal:  Clin Res Cardiol       Date:  2006-02-17       Impact factor: 5.460

5.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

6.  Species differences in Cl- affinity and in electrogenicity of SLC26A6-mediated oxalate/Cl- exchange correlate with the distinct human and mouse susceptibilities to nephrolithiasis.

Authors:  Jeffrey S Clark; David H Vandorpe; Marina N Chernova; John F Heneghan; Andrew K Stewart; Seth L Alper
Journal:  J Physiol       Date:  2008-01-03       Impact factor: 5.182

Review 7.  Oxalosis in primary hyperoxaluria in infancy : Report of a case in a 3-month-old baby. Follow-up for 3 years and review of literature.

Authors:  Cinzia Orazi; Stefano Picca; Paolo M S Schingo; Fausto M Fassari; Giuseppe Canepa
Journal:  Skeletal Radiol       Date:  2009-01-09       Impact factor: 2.199

8.  Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver-kidney transplantation for primary hyperoxaluria type 1.

Authors:  Eliza Lee; Gabriel Ramos-Gonzalez; Nancy Rodig; Scott Elisofon; Khashayar Vakili; Heung Bae Kim
Journal:  Pediatr Nephrol       Date:  2017-12-14       Impact factor: 3.714

9.  Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.

Authors:  Chaitali Dutta; Nicole Avitahl-Curtis; Natalie Pursell; Marita Larsson Cohen; Benjamin Holmes; Rohan Diwanji; Wei Zhou; Luciano Apponi; Martin Koser; Bo Ying; Dongyu Chen; Xue Shui; Utsav Saxena; Wendy A Cyr; Anee Shah; Naim Nazef; Weimin Wang; Marc Abrams; Henryk Dudek; Eduardo Salido; Bob D Brown; Chengjung Lai
Journal:  Mol Ther       Date:  2016-01-13       Impact factor: 11.454

10.  Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.

Authors:  Theresa Ermer; Christoph Kopp; John R Asplin; Ignacio Granja; Mark A Perazella; Martin Reichel; Thomas D Nolin; Kai-Uwe Eckardt; Peter S Aronson; Fredric O Finkelstein; Felix Knauf
Journal:  Kidney Int Rep       Date:  2017-06-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.